References
- Korea National Statistical Office. Statistical Yearbook, 2002
- Anderson, K., Launer, L. J., Ott, A., Hoes, A. W., Breteler, M. M. and Hofman, A. : Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45, 1441 (1995) https://doi.org/10.1212/WNL.45.8.1441
-
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B. and Landreth, G. E. : Inflammatory mechanism in Alzheimer's disease: inhibition of
$\beta$ -amyloid-stimulated proinflammatory responses and neurotoxicity by PPAR gamma agonists. J. Neurosci. 20, 558 (2000) - Grundman, M., Corey-Bloom, J. and Thai, L. J. : Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs. J. Neural. Transm. Suppl. 53, 255 (1998)
- Oka, A. and Takashima, S. : Introduction of cyclooxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport 8, 1161 (1997) https://doi.org/10.1097/00001756-199703240-00020
- Pasinetti, G. M. : Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J. Neurosci. Res. 54, 1 (1998) https://doi.org/10.1002/(SICI)1097-4547(19981001)54:1<1::AID-JNR1>3.0.CO;2-M
- Kish, S. J., Mastrogiacomo, F., Guttman, M., Furukawa, Y., Taanman, J. W., Dozic, S., Pandolfo, M., Lamarche, J., DiStefano, L. and Chang, L. J. : Decreased brain protein levels of cytochrome oxidase subunits in Alzheimer's disease and in hereditary spinocerebellar ataxia disorders: a nonspecific change? J. Neurochem. 72, 700 (1997) https://doi.org/10.1046/j.1471-4159.1999.0720700.x
-
Montine, T. J., Sidell, K. R., Crews, B. C., Markesbery, W. R., Marnett, L. J., Roberts, L. J. and Morrow, J, D. : Elevated CSF prostaglandin
$E_2$ levels in patients with probable AD. Neurology 53, 1495 (1999) https://doi.org/10.1212/WNL.53.7.1495 - Kiminobu, S., Tolga, U., Vinod, K. and Hari, M. : New anti-inflammatory treatment strategy in Alzheimer's disease. Jpn. J Pharmacol. 82, 85 (2000) https://doi.org/10.1254/jjp.82.85
- Tocco, G., Freire-Moar, J., Schreiber, S. S., Sakhi, S. H., Aisen, P. S. and Pasinetti, G. M. : Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp. Neurol. 144, 339 (1997) https://doi.org/10.1006/exnr.1997.6429
- McGeer, P. L., Schulzer, M. and McGeer, E. G. : Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425 (1996) https://doi.org/10.1212/WNL.47.2.425
- Dray, F., Mamasd, S. and Bizzini, B. : Problems of PGE antisera specificity. Meth. Enzymol. 86, 258 (1982) https://doi.org/10.1016/0076-6879(82)86198-3
- hanmugam, P., Feng, L., Liou, S., Jang, B., Boudreau, M., Yu, G., Lee, J., Kwon, H., Beppu, T., Yoshida, M., Xia, Y., Wilson, C. B. and Hwang, D. : Radicinol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysacch-aride and in experimental glomerulo-nephritis. J Biol. Chem. 270, 5418 (1995) https://doi.org/10.1074/jbc.270.10.5418
- Lap, H., Cristiana, P., David, W., Dushyant, P. P., Paul, S. A. and Pasinetti, G. M. : Regional distribution of cyclooxygenase-2 in the hippocampal formation Alzheimer's disease. J. Neurosci. Res. 57, 295 (1999) https://doi.org/10.1002/(SICI)1097-4547(19990801)57:3<295::AID-JNR1>3.0.CO;2-0
- Herschman, H. R. ; Prostaglandin synthase 2. Biochim. Biophys. Acta 1299, 125 (1996) https://doi.org/10.1016/0005-2760(95)00194-8
- McKenna, M. T., Proctor, G. R, Young, L. C. and Harvey, A. L. : Novel tacrine analogues for potential use against Alzheimer's disease: Potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors. J Med. Chem. 40, 3516 (1997) https://doi.org/10.1021/jm970150t
- Yasojima, K., Schwab, C., Mcgeer, E. G. and Mcgeer, P. L. : Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain. Res. 830, 226 (1999) https://doi.org/10.1016/S0006-8993(99)01389-X
- Yermakova, A. V., Rollins, J., Callahan, L. M., Rogers, J, and O'Banion. M. K. : Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J. Neurpathol. Exp. Neuol. 58, 1135 (1999) https://doi.org/10.1097/00005072-199911000-00003
- O'Banion, M. K., Chang, J. W., Kaplan, M. D., Yermakova, A. and Coleman, P. D. : Glial and neuronal expression of cyclooxygenase-2: relevance to Alzheimer disease. Adv. Exp. Med. Biol. 433, 177 (1997)
- Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszinak, A. W., Zalinski, J., Cofeld, M., Mansukhani, L., Willson, P. and Korgan, F. : Clinical trial of indometacin in Alzheimer's disease. Neurology 43, 1609 (1993) https://doi.org/10.1212/WNL.43.8.1609
- Aisen, J. S. and Davis, K. L. : Inflammatory mechanism in Alzheimer's disease: implications for therpy. Am. J. Psychiat. 151, 1105 (1994) https://doi.org/10.1176/ajp.151.8.1105
- Lukiw, W. J. and Bazan, N. G. : Cyclooxygenase 2 RNA message adundance. stability and hypervariability in sporadic Alzheimer neocortex. J. Neurosci. Res. 50, 937 (1997) https://doi.org/10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E